Regenstrief Institute Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2009
NCT00842608
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Regenstrief Institute, Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

haloperidol (haldol) (2 trials)

Drugs in Phase 2 Trials (1)

erenumab (aimovig) (1 trial)

Drugs in Other Trials (3)

donepezil (aricept) (1 trial)

galantamine (reminyl) (1 trial)

rivastigmine (exelon) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cognitive Dysfunction (Phase 4)

Delirium (Phase 4)

Depression (Phase 4)

Stress Disorders, Post-Traumatic (Phase 4)

Stress Disorders, Traumatic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 5